Pieris Pharmaceuticals Stock Set to Reverse Split on Tuesday, April 23rd (NASDAQ:PIRS)

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) shares are scheduled to reverse split on Tuesday, April 23rd. The 1-80 reverse split was announced on Tuesday, April 23rd. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, April 23rd.

Pieris Pharmaceuticals Price Performance

PIRS stock traded down $0.01 during trading hours on Friday, reaching $0.15. The stock had a trading volume of 1,919,826 shares, compared to its average volume of 580,219. The stock has a market capitalization of $14.34 million, a PE ratio of -0.53 and a beta of 0.48. The stock has a 50-day simple moving average of $0.17 and a 200 day simple moving average of $0.20. Pieris Pharmaceuticals has a fifty-two week low of $0.14 and a fifty-two week high of $1.01.

Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings results on Friday, March 29th. The biotechnology company reported ($0.05) EPS for the quarter. The firm had revenue of $1.30 million during the quarter. Pieris Pharmaceuticals had a negative net margin of 57.33% and a negative return on equity of 90.17%.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on shares of Pieris Pharmaceuticals in a research note on Saturday, April 13th. They set a “hold” rating for the company.

Institutional Trading of Pieris Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. increased its holdings in Pieris Pharmaceuticals by 149.9% in the 1st quarter. JPMorgan Chase & Co. now owns 63,643 shares of the biotechnology company’s stock valued at $193,000 after buying an additional 38,179 shares during the period. Oppenheimer & Co. Inc. bought a new position in Pieris Pharmaceuticals in the 1st quarter valued at about $32,000. Healthcare of Ontario Pension Plan Trust Fund bought a new position in Pieris Pharmaceuticals in the 1st quarter valued at about $1,263,000. BlackRock Inc. increased its holdings in Pieris Pharmaceuticals by 1.6% in the 1st quarter. BlackRock Inc. now owns 1,338,437 shares of the biotechnology company’s stock valued at $4,055,000 after buying an additional 21,150 shares during the period. Finally, Blair William & Co. IL increased its holdings in Pieris Pharmaceuticals by 9.1% in the 1st quarter. Blair William & Co. IL now owns 128,745 shares of the biotechnology company’s stock valued at $390,000 after buying an additional 10,760 shares during the period. Institutional investors and hedge funds own 40.11% of the company’s stock.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.